Therapeutic potential of GLP-1 agonists for hidradenitis suppurativa
- PMID: 37897079
- DOI: 10.1111/ijd.16892
Therapeutic potential of GLP-1 agonists for hidradenitis suppurativa
References
-
- Amat-Samaranch V, Agut-Busquet E, Vilarrasa E, Puig L. New perspectives on the treatment of hidradenitis suppurativa. Ther Adv Chronic Dis. 2021;12:204062232110559. https://doi.org/10.1177/20406223211055920
-
- Novo Nordisk Inc. Victoza. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022341s027lbl.pdf. Revised August 2017. Accessed April 17, 2023.
-
- Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606-1616.
-
- Novo Nordisk Inc.Wegovy. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl..... Revised June 2021. Accessed April 17,2023.
-
- Collins L, Costello RA. Glucagon-like peptide-1 receptor agonists. StatPearls. Treasure Island, FL: StatPearls Publishing; 2022.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
